ArticleJournal of hepato-biliary-pancreatic sciences2026
Clinical Implications of Ki-67 Index, Grade and Hormonal Changes in Pancreatic Neuroendocrine Tumors: Insights Into Tumor Heterogeneity Based on Primary and Secondary Lesions.
Article in Journal of hepato-biliary-pancreatic sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reply: Refining Prognostic Stratification in Grade 2 Pancreatic Neuroendocrine Tumors.Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPancreatic neuroendocrine tumors (PanNETs) show heterogeneity, including temporal shifts in proliferation and hormone production; however, their clinical implications remain uncertain.
methodsThis retrospective study included 114 patients with metastatic or recurrent PanNETs at Kyushu University Hospital. Paired specimens from 46 patients (27 synchronous metastases and 19 recurrences) were evaluated for Ki-67 index and tumor grade. Proliferation change was defined as grade progression or a ≥ 10% absolute Ki-67 increase. Hormonal phenotype changes were assessed in all patients.
resultsIn metastases, mean Ki-67 increased from 12.3% to 16.4% (p = 0.0043); 22.2% showed a ≥ 10% increase, and 33.3% progressed in grade. In recurrences, Ki-67 increased from 8.8% to 9.3% (p = 0.8256); 15.8% showed a ≥ 10% increase, and 21.1% progressed in grade. Median progression-free survival was 7.8 months in metastases and 17.1 months in recurrences. Median overall survival was significantly longer in the recurrence group (124.8 vs. 32.5 months, p = 0.003). Hormonal transformation occurred in six patients (5.3%), mostly during progressive hepatic disease.
conclusionA subset of PanNETs exhibited increased proliferation of metastases or recurrence without detrimental survival effects, possibly because of timely treatment adjustments. Rebiopsy may be useful for detecting proliferative changes, whereas hormonal shifts highlight tumor heterogeneity and warrant continued clinical and biochemical monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.